Core Viewpoint - The company held a performance briefing for the fiscal year 2024 and the first quarter of 2025, discussing its business transformation plans and financial performance [1][2]. Group 1: Meeting Details - The performance briefing took place on May 13, 2025, from 11:00 to 12:00 via the Shanghai Stock Exchange Roadshow Center [1]. - Key attendees included the Chairman, CEO, CFO, and independent directors, who engaged with investors through an interactive online format [1]. Group 2: Business Transformation and Progress - The company is focusing on deepening its industrial layout and enhancing market competitiveness, particularly in the judicial IVD sector, with plans for independent R&D and market penetration of DNA testing products [2]. - In the pharmaceutical distribution sector, the company aims to optimize hospital channel management and expand its chain franchise business [2]. - The pharmaceutical manufacturing segment will enhance operational efficiency through organizational restructuring and brand building, with a focus on core products like eye drops [2]. Group 3: Revenue Structure and Performance - The company reported a total revenue of 78.61 million for Q1 2025, with a net profit of 3.14 million, marking a turnaround from losses [9]. - The revenue contributions from different business segments for 2024 were as follows: - Pharmaceutical distribution: 182 million, down 9.34% year-on-year - Judicial IVD: 119 million, up 1.6% year-on-year - Pharmaceutical manufacturing: 35.45 million, down 20% year-on-year [5][6]. Group 4: Future Growth and Market Strategy - The company plans to continue optimizing its business structure, focusing on high-tech development and core biotechnology [8]. - Future growth will be driven by expanding into the health and judicial IVD sectors, leveraging both internal and external growth strategies [10]. - The company is also addressing potential impacts from the US-China trade war by seeking non-US suppliers and promoting domestic product alternatives [12].

Core Viewpoint - The livestock farming index in China has shown a slight decline, with specific stocks experiencing mixed performance, while external factors such as foot-and-mouth disease in South Africa are impacting the industry [1][3]. Group 1: Market Performance - As of May 13, 2025, the China Livestock Farming Index (930707) decreased by 0.38%, with stocks like Luyouli (300381) and Jinxinnong (002548) showing gains of 1.07% and 1.05% respectively, while Ruipubio (300119) led the decline with a drop of 2.66% [1]. - The Livestock ETF (516760) fell by 0.80%, with a latest price of 0.62 yuan, but it ranked first in weekly performance among comparable funds as of May 12, 2025 [1]. - The Livestock ETF had a turnover rate of 1.07% during the trading session, with a total transaction value of 1.4475 million yuan, and an average daily transaction of 4.6547 million yuan over the past year [3]. Group 2: Industry Insights - The South African Department of Agriculture confirmed the spread of foot-and-mouth disease to provinces like KwaZulu-Natal, prompting China's Ministry of Agriculture to urge livestock farmers to restrict animal transport and implement a 28-day quarantine for new animals [1]. - Everbright Securities identified three main investment themes: (1) Planting: Rising prices of staple crops like corn and wheat are expected to benefit major planting companies; (2) Seeds: Improved demand in the seed industry due to favorable planting conditions; (3) Agricultural Chemicals: Improved planting profits are likely to reduce agricultural input cost pressures, expanding the agricultural chemicals market [1]. Group 3: Valuation Metrics - The Livestock ETF closely tracks the China Livestock Farming Index, which includes companies involved in animal feed, veterinary drugs, and livestock farming, reflecting the overall performance of related listed companies [3]. - As of May 12, 2025, the Livestock Farming Index's price-to-earnings ratio (PE-TTM) was 12.26, indicating it is at a historical low, being below 99.43% of the time over the past year [3]. - The top ten weighted stocks in the Livestock Farming Index accounted for 69.38% of the index, with Hai Da Group (002311) having the highest weight at 11.24% [3][5].

Investment Rating - Industry Rating: Outperform the market (maintained rating) [12] Core Views - The pet sector continues to show high prosperity, driven by domestic substitution and consumption upgrades, leading to a dual increase in volume and price [1][2] - The industry is transitioning from "scale expansion" to "value creation," with leading companies shifting from "manufacturing" to "intelligent manufacturing" through formula innovation and precise demand capture [2][17] - The domestic pet food market remains strong, with a significant increase in sales and exports, indicating robust growth potential for domestic brands [2][17] Summary by Sections Pet Sector - The fifth TOPS Pet Expo in Shanghai showcased over 1,200 exhibitors and 8,000+ brands, reflecting strong growth momentum in the pet industry, with a 43% year-on-year increase in attendance [1][16] - Trends in pet food are shifting towards precision nutrition, with a focus on age-specific feeding and high-end production techniques [1][16] - Key recommended companies in the pet food sector include Guibao Pet, Zhongchong Co., Petty Co., and Lusi Co., with additional recommendations for pet medical and product companies [2][17] Swine Sector - As of May 10, the average price of live pigs was 14.90 yuan/kg, showing a slight decline, with production capacity continuing to grow [3][18] - The industry is facing a potential downturn in profitability due to weak demand and seasonal price declines [3][19] - Recommended companies include leading players such as Wens Foodstuffs and Muyuan Foods, with a focus on core assets [19] Poultry Sector - The white chicken segment is facing uncertainties in breeding imports, with a significant decline in the number of breeding stock updated [20][21] - The yellow chicken segment is expected to benefit from improved consumer demand, with stable prices observed [23] - Recommended companies include Shengnong Development and Lihua Co. for white chicken, and Wens Foodstuffs for yellow chicken [22][23] Planting Sector - The government emphasizes agricultural technology innovation and self-sufficiency in food security, with a focus on biological breeding [25][26] - Recommended companies in the seed sector include Longping High-Tech and Dabeinong, with additional focus on agricultural water-saving technologies [25][26] Feed and Animal Health Sector - Hai Da Group is highlighted for its market share growth and consistent performance in the feed sector [27] - The animal health sector is seeing new opportunities in pet health products, with recommended companies including KQ Bio and Zhongmu Co. [28]

Core Viewpoint - The investigation into Liu Datao, the chairman and general manager of Maiwei Biotech, by the China Securities Regulatory Commission (CSRC) for suspected short-term trading does not significantly impact the company's daily operations [1][2] Company Overview - Maiwei Biotech was established in 2017, focusing on the research, production, and sales of innovative drugs and biosimilars, primarily targeting oncology and age-related diseases [1][2] - The company has three products on the market: Junmaikang, Mailishu, and Maiweijian, but remains unprofitable with cumulative losses [3] Financial Performance - For 2024, Maiwei Biotech reported revenue of 200 million yuan, with 145 million yuan from drug sales and 55.03 million yuan from technical services [3] - The company experienced a 33.7% year-on-year decline in revenue for Q1 2025, with net losses increasing from 206 million yuan to 292 million yuan [4] - R&D expenses remain high, with 783 million yuan spent in the previous year, despite a 6.33% decrease compared to the prior year [3] Shareholding and Management - Liu Datao holds a 3.78% stake in the company, amounting to 15.1 million shares, all of which are subject to lock-up agreements [2] - The actual controllers of Maiwei Biotech are Tang Chunshan and Chen Shanna, with Tang being one of the founders and currently serving as an executive director [2] Debt and Financing Strategy - The company's debt ratio increased significantly from 42.24% at the end of 2023 to 63.61% at the end of 2024 [4] - To address funding issues, Maiwei Biotech has applied for a listing on the Hong Kong Stock Exchange and plans to issue up to 500 million yuan in targeted debt financing tools [4]

Core Viewpoint - The livestock farming sector is experiencing a positive trend, with an extended profit period expected for pig farming, driven by improved demand and favorable pricing dynamics [1][2]. Group 1: Market Performance - As of May 7, 2025, the China Livestock Breeding Index (930707) increased by 0.20%, with key stocks such as Shengnong Development (002299) rising by 1.89% and Yiduoli (300381) by 1.75% [1]. - The Livestock ETF (516760) rose by 0.16%, with a recent price of 0.63 yuan, and has seen a cumulative increase of 7.19% over the past three months, ranking in the top 25% among comparable funds [1]. - The average price of pork in national wholesale markets reached 20.96 yuan/kg on May 6, 2025, marking a 1.8% increase compared to pre-holiday levels [1]. Group 2: Financial Performance - In 2024, pig farming enterprises are projected to generate revenues of 437 billion yuan, a year-on-year decline of 1.28%, while net profit attributable to shareholders is expected to rise by 337.73% to 32 billion yuan [1]. - In Q1 2025, pig farming enterprises achieved revenues of 107.88 billion yuan, reflecting an 18.69% year-on-year increase, with industry net profit reaching 7.91 billion yuan, up 236.12% year-on-year [1]. Group 3: Supply and Demand Dynamics - As of Q2 2025, domestic demand for pigs is showing marginal improvement, with price support and a gradual transition into a phase of price increases [2]. - External factors, including rising feed raw material prices due to tariffs and increased costs of imported meat, are also contributing to favorable pricing for pigs [2]. Group 4: Valuation Metrics - The Livestock ETF, which tracks the China Livestock Breeding Index, has a current price-to-earnings ratio (PE-TTM) of 12.38, placing it in the 1.74% percentile over the past year, indicating a valuation lower than 98.26% of the time in the last year [2]. - The China Livestock Breeding Index includes companies involved in livestock feed, veterinary drugs, and livestock farming, reflecting the overall performance of related listed companies [2]. Group 5: Top Weighted Stocks - As of April 30, 2025, the top ten weighted stocks in the China Livestock Breeding Index include Haida Group (002311), Muyuan Foods (002714), and Wens Foodstuff Group (300498), collectively accounting for 69.38% of the index [2].

Investment Rating - The investment rating for the agriculture, forestry, animal husbandry, and fishery industry is "Positive" (maintained) [2] Core Insights - The agricultural industry achieved a revenue of CNY 11,498.20 billion in 2024, a year-on-year decrease of 3.68%, while the net profit attributable to shareholders rose to CNY 466.39 billion, an increase of 806.55% [6][17] - In Q1 2025, the industry reported a revenue of CNY 2,706.77 billion, a year-on-year growth of 6.79%, with a net profit of CNY 133.13 billion, up 795.07% [6][17] - The overall profitability of the industry improved significantly in Q1 2025, with gross profit margin at 12.91%, net profit margin at 5.16%, and return on equity (ROE) at 2.57%, all showing year-on-year increases [21][30] Summary by Sections Overall Industry Performance - In 2024, the agricultural industry saw a slight decline in revenue but a substantial increase in net profit, indicating improved profitability despite lower sales [17] - The profitability metrics for Q1 2025 showed significant improvements compared to the previous year, with a notable decrease in the expense ratio [21] Sub-industry Analysis - The livestock sector experienced a remarkable increase in net profit, with pig farming turning profitable in 2024 and continuing strong performance into 2025 [6][29] - The poultry farming sector also showed strong growth, with net profit increasing significantly due to reduced feed costs and improved efficiency [43][44] - The pet food sector maintained high growth rates, with revenues and profits continuing to rise [6][25] Livestock Farming - In 2024, pig farming companies generated CNY 4,370.03 billion in revenue, a slight decline, but net profit surged to CNY 320.13 billion, reflecting a recovery in profitability [29] - In Q1 2025, revenues for pig farming increased by 18.69% year-on-year, with net profit rising by 236.12% [29][30] Poultry Farming - Poultry farming companies achieved a revenue of CNY 520.71 billion in 2024, with a net profit of CNY 28.49 billion, marking a significant increase [43] - In Q1 2025, revenue continued to grow, reaching CNY 118.71 billion, with net profit increasing to CNY 4.51 billion [43][44] Feed Industry - The feed industry reported a revenue of CNY 1,863.30 billion in 2024, with a net profit of CNY 52.48 billion, showing a significant recovery in profitability [58] - In Q1 2025, revenues rose to CNY 428.66 billion, with net profit increasing to CNY 15.26 billion [58][61] Animal Health - The animal health sector saw a revenue of CNY 129.02 billion in 2024, with a net profit of CNY 10.82 billion, despite a decline in profitability [66] - In Q1 2025, revenues increased to CNY 30.96 billion, with net profit rising to CNY 4.26 billion [66]

盈利预测与投资建议。预计2025-2027 年EPS 分别为0.23 元、0.28 元、0.33元，对应动态PE 分别为 30/25/21 倍，维持"持有"评级。 风险提示：产品研发不及预期、产品销售情况不及预期、养殖业突发疫情等风险。 业绩总结：2024年公司实现营业收入12.55亿元，同比降低21.45%，归母净利润为1.09 亿元，同比降低 61.57%。2025 年第一季度公司实现营业收入3.52亿元，同比增长1.06%；归属于上市公司股东的净利润 0.76 亿元，同比降低27.57%。 养殖行业公司资金压力降低或提升动保产品采购意愿。2024年公司各业务板块表现分化，反刍业务显韧 性，新品提供增长潜力。猪用疫苗方面行业竞争激烈导致猪苗板块整体承压。口蹄疫疫苗作为公司基石 产品，市占率保持稳定，但面临价格压力。猪圆环疫苗凭借产品品质实现销量同比大幅上涨52.17%， 但价格同样承压。猪伪狂犬活疫苗销量同比增长28.25%。猪瘟、圆支二联等产品销量有所下滑。反刍 疫苗在下游养殖行情低迷背景下仍具韧性。公司在布病防控领域具备多品类组合和差异化竞争优势，但 受政府招采节奏等因素影响，布病疫苗销量同比下滑1. ...

金宇生物技术股份有限公司 2024 年年度股东大会会议资料 二○二五年五月 金宇生物技术股份有限公司 2024 年年度股东大会会议资料 金宇生物技术股份有限公司 2024 年年度股东大会会议议程 会议时间：2025 年 5 月 28 日（星期三）14：00 会议地点：公司会议室 主 持 人：董事长张翀宇 | 序号 | 会议议程 | 文件号 | | --- | --- | --- | | | 主持人介绍出席会议人员到会情况及会议召开的合法有效 | | | | 性,介绍会议主要议题，宣布会议正式开始 | | | 1 | 公司 2024 年度董事会工作报告 | 文件之一 | | 2 | 公司 2024 年度监事会工作报告 | 文件之二 | | 3 | 公司 2024 年年度报告及摘要 | 文件之三 | | 4 | 公司 2024 年度财务工作报告 | 文件之四 | | 5 | 公司 2024 年度利润分配预案 | 文件之五 | | 6 | 公司 年度独立董事述职报告 2024 | 文件之六 | | 7 | 关于公司为子公司银行综合授信提供担保的议案 | 文件之七 | | 8 | 关于续聘公司 2025 年度审计机构 ...

证券代码：600201 证券简称：生物股份 公告编号：临2025-026 金宇生物技术股份有限公司关于 以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司应当在每个月的前 3 个交易日内披露截至上月 末的回购进展情况。现将回购进展情况公告如下： 2025 年 4 月，公司通过上海证券交易所系统以集中竞价交易方式累计回购公 司股份 80.33 万股，占公司总股本的比例为 0.0717%，成交最高价为 7.30 元/股， 最低价为 6.79 元/股，已支付的金额为 569.78 万元（不含佣金、过户费等交易费 用）。 截至 2025 年 4 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易方 式累计回购公司股份 1,538.33 万股，占公司总股本的比例为 1.3731%，成交最高 价为 7.30 元/股，成交最低价为 6.37 元/股，支付的资金总额为 10,555.22 万元 ...

证券代码：600201 证券简称：生物股份 公告编号：2025-025 金宇生物技术股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 28 日 14 点 00 分 召开地点：内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金宇大 街 1 号公司会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 28 日 至2025 年 5 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 方式 股东大 ...